16 / 39
OS with One Prior Anti-Angiogenic Therapy in Patients With mRCC
0. 0
0
3
6
1 2
9
1 5
Months
1 8
2 1
2 4
27
3 0
3 3
0. 3
0. 1
0. 2
0. 4
0. 5
0. 6
0. 7
0. 8
0. 9
1 .0
Nivolumab
Everolimus
Number of patients at risk
Nivolumab
317
277
233
163
52
2
Everolimus
312
248
203
142
49
1
Overall Survival (Probability)
HR (95% CI
), 0.79 (0.63–0.99)
Median OS, months
(95% CI)
Nivolumab
23.6 (20.8–NE)
Everolimus
19.9 (17.7–24.7)
Adapted from Motzer et al, 2016, ASCO GU.